Press releases

Regulatory

May 19, 2022

Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue

Read more

Regulatory

April 26, 2022

Interim report January-March 2022

Read more

Regulatory

March 21, 2022

Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million

Read more

Regulatory

February 17, 2022

Significant progress towards Emcitate® marketing applications in the US and Europe in 2023

Read more

Regulatory

January 18, 2022

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

Read more

Regulatory

December 13, 2021

Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data

Read more

Regulatory

November 4, 2021

Interim report January-September 2021

Read more

Regulatory

August 19, 2021

Emcitate development program progressing according to plan

Read more

Regulatory

April 19, 2021

Egetis Therapeutics appoints Yilmaz Mahshid as new CFO

Read more

Regulatory

March 26, 2021

Dr Thomas Lönngren nominated as new Chairman of the Board at Egetis Therapeutics

Read more